Ibalizumab治疗耐多药HIV-1感染的研究进展  

Research advances of ibalizumab in the treatment of multidrug-resistant HIV-1 infection

作　　者：万艳 李宏 WAN Yan;LI Hong(Department of Infectious Disease,Affiliated Hospital of Guizhou Medical University,Guiyang 550004,China)

机构地区：[1]贵州医科大学附属医院感染科,贵阳550004

出　　处：《传染病信息》2022年第2期182-185,共4页Infectious Disease Information

基　　金：贵州省卫生健康委科学技术基金(2019-1-082);贵州省科技计划项目([2020]1Y299);国家自然科学基金(82060123)。

摘　　要：Ibalizumab是一种人源化免疫球蛋白G4单克隆抗体,其在阻断HIV-1进入CD4^(+) T淋巴细胞的同时,可保持人体正常免疫功能。鉴于此,临床逐步将ibalizumab与其他抗反转录病毒药物联合应用于治疗耐多药HIV-1感染,相关研究已经取得了较大进展。目前,ibalizumab是第一个被美国FDA批准用于治疗HIV-1感染的单克隆抗体,有望成为治疗耐多药HIV-1感染的新选择。本文综述了ibalizumab治疗成人耐多药HIV-1感染的药理学特性及临床疗效,为耐多药HIV-1感染的治疗提供参考。Ibalizumab, a humanized immunoglobulin G4 monoclonal antibody, blocks HIV-1 entry into CD4^(+) T lymphocytes while preserving normal immune function of human body. Thereforem ibalizumab in combination with other antiretroviral(s) is indicated in clinical treatment of multidrug-resistant HIV-1 infection, and has achieved great progress in related research. Ibalizumab is the first monoclonal antibody approved by the U.S. FDA for the treatment of HIV-1 infection and provided a new choice for the treatment of multi drug-resistant HIV-1 infection. This article reviews the pharmacological properties and clinical efficacy of ibalizumab in the treatment of adult multidrug-resistant HIV-1 infection, and provides references for the treatment of multidrug-resistant HIV-1 infection.

关 键 词：ibalizumab 耐多药 抗病毒活性 单克隆抗体 交叉耐药 药代动力学特性 临床研究 

分 类 号：R512.91[医药卫生—内科学]